Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.
<h4>Background</h4>The Xarelto Post-Authorization Safety and Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS) was designed to investigate safety and effectiveness during long-term follow-up of rivaroxaban treatment, using reduced doses compared with other global...
Saved in:
Main Authors: | Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b4c49a7ceb404b83a60b6d9e87b35dea |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)
by: Ikuo Fukuda, et al.
Published: (2021) -
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
by: Hsin-Yi Huang, et al.
Published: (2018) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
by: Victoria Speed, et al.
Published: (2021) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014) -
Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
by: Jiaming (Calvin) Liang, MD, MSc, et al.
Published: (2021)